Bellevue Group AG Grows Position in Autolus Therapeutics plc (NASDAQ:AUTL)

Bellevue Group AG boosted its holdings in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 27.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,500 shares of the company’s stock after acquiring an additional 9,000 shares during the period. Bellevue Group AG’s holdings in Autolus Therapeutics were worth $151,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in AUTL. FMR LLC boosted its stake in shares of Autolus Therapeutics by 44.6% during the third quarter. FMR LLC now owns 17,773,873 shares of the company’s stock valued at $64,519,000 after purchasing an additional 5,478,706 shares in the last quarter. Great Point Partners LLC lifted its holdings in Autolus Therapeutics by 195.0% during the second quarter. Great Point Partners LLC now owns 3,441,667 shares of the company’s stock worth $11,977,000 after buying an additional 2,275,000 shares during the period. Armistice Capital LLC boosted its position in Autolus Therapeutics by 33.8% during the 2nd quarter. Armistice Capital LLC now owns 6,250,000 shares of the company’s stock valued at $21,750,000 after acquiring an additional 1,578,000 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Autolus Therapeutics by 74.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 2,531,688 shares of the company’s stock valued at $8,810,000 after acquiring an additional 1,080,897 shares during the period. Finally, Affinity Asset Advisors LLC raised its position in shares of Autolus Therapeutics by 27.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company’s stock worth $14,964,000 after acquiring an additional 925,000 shares in the last quarter. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Stock Up 1.5 %

AUTL opened at $3.32 on Monday. The company has a market cap of $883.42 million, a P/E ratio of -2.74 and a beta of 2.04. The firm’s 50-day moving average price is $3.72 and its 200-day moving average price is $3.91. Autolus Therapeutics plc has a 52-week low of $2.69 and a 52-week high of $7.45.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period last year, the firm earned ($0.26) EPS. On average, research analysts anticipate that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. The Goldman Sachs Group upgraded Autolus Therapeutics from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $7.00 to $7.60 in a research note on Monday, November 18th. Redburn Atlantic upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price for the company in a research note on Friday, November 15th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 price target on shares of Autolus Therapeutics in a research report on Monday, November 11th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $10.15.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.